Proceedings | Boulder Peptide Symposium

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado
The only conference focused solely on the pharmaceutical development of peptide therapeutics.

BPS 2022


Start-up Workshop Panel

Cristina Rondinone

Founder/CEO, Pep2Tango Therapeutics Inc

ABSTRACT

Pep2Tango Therapeutics, a new biotech startup developing novel peptides for a number of chronic diseases.

BIO

Cristina M. Rondinone, Ph.D.
Senior executive and leader with more than 20 years of experience in the bio pharmaceutical industry with a record of successfully leading teams for the discovery and development of numerous medicines. Founder and CEO of Pep2Tango Therapeutics, a new biotech start up. Member of the Board of Directors at Axcella (AXLA) and member of the Health Council at TECNALIA. Senior Consultant. Former President of Cellarity Inc (a Flagship company) and former Senior Vice President of AstraZeneca (Medimmune), Head Cardiovascular, Metabolic and Renal Diseases. Set the strategy for the company/area and built the portfolio of programs and productive teams. During her career progressed many molecules (more than 15) from target identification to late stage clinical trials. Prior to MedImmune, she held leadership positions at Hoffmann-La Roche, as well as at Abbott Laboratories. Before joining the pharmaceutical industry, she was Associate Professor (Docent) of Molecular Medicine at the University of Gothenburg in Sweden and received her Ph.D. in Biochemistry from the University of Buenos Aires. Her postdoctoral training was at the Laboratory of Cellular and Developmental Biology at NIDDK, National Institutes of Health, USA. Authored more than 80 scientific publications and 5 patents. Inducted as a Member of the Royal Academy of Pharmacy and Biochemistry, Spain.


s2Member®
loading...